Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    2772657 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
Condition: Cystic Fibrosis
Intervention: Drug: tobramycin
2 Recruiting The Role of Bacteria and Genetic Variations in Cystic Fibrosis
Condition: Lung Diseases
Intervention:

Indicates status has not been verified in more than two years